| Dec'19 | Dec'18 | |||||
|---|---|---|---|---|---|---|
Cash flows from operating activities | ||||||
Net loss | ||||||
-7,704 | -2,495 | |||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation expense | ||||||
1 | 1 | |||||
Research and development-acquired license, expensed | ||||||
95 | 132 | |||||
Stock issued for research and development | ||||||
- | 36 | |||||
Stock-based compensation | ||||||
2,495 | 143 | |||||
Unrealized loss on marketable securities | ||||||
3 | - | |||||
Changes in assets and liabilities: | ||||||
Prepaid expenses | ||||||
97 | 12 | |||||
Accrued salaries and benefits | ||||||
- | -1 | |||||
Accounts payable | ||||||
267 | 94 | |||||
Net cash used in operating activities | ||||||
-4,947 | -2,102 | |||||
Cash flows from investing activities | ||||||
Purchase of marketable securities | ||||||
800 | - | |||||
Purchase of research and development licenses | ||||||
95 | - | |||||
Net cash provided by (used in) investing activities | ||||||
-895 | - | |||||
Cash flows from financing activities | ||||||
Proceeds from issuance of Series A Convertible Preferred Stock and warrants for cash in an offering, net | ||||||
- | 1,186 | |||||
Proceeds from issuance of common stock in the IPO, net of offering cost | ||||||
5,840 | - | |||||
Proceeds from issuance common stock and warrants, net of offering cost | ||||||
1,610 | - | |||||
Proceeds from exercise of warrants | ||||||
0 | - | |||||
Payment of employee withholdings for vested restricted stock | ||||||
- | 31 | |||||
Net cash provided by financing activities | ||||||
7,450 | 1,154 | |||||
Net increase (decrease) in cash | ||||||
1,608 | -947 | |||||
Non-cash investing and financing activities | ||||||
Conversion of preferred stock to common stock upon completion of the IPO | ||||||
0 | - | |||||
Common stock issued for acquired license | ||||||
- | 132 | |||||
Cashless warrant exercise | ||||||
0 | - | |||||
Offering cost included in accrued expenses | ||||||
30 | 206 | |||||